$OPK
OPKO HEALTH, INC. Stock $opk

$opk Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000094480923000021 Filed on May 03, 2023

Income Statement

Concept	2023 Q2	2023 Q1
Revenue	$265.4M	$237.6M
YoY Change	-14.36%	-27.84%
Cost Of Revenue	$138.9M	$138.3M
YoY Change	-28.52%	-43.28%
Gross Profit	$126.5M	$99.26M
YoY Change	9.45%	16.31%
Gross Profit Margin	47.66%	41.78%
Selling, General & Admin	$79.80M	$75.64M
YoY Change	-21.35%	-35.64%
% of Gross Profit	63.08%	76.2%
Research & Development	$18.20M	$32.61M
YoY Change	5.48%	78.05%
% of Gross Profit	14.39%	32.85%
Depreciation & Amortization	$21.50M	$26.45M
YoY Change	-23.2%	-4.92%
% of Gross Profit	17.0%	26.64%
Operating Expenses	$119.5M	$268.2M
YoY Change	-62.73%	-33.23%
Operating Profit	$7.000M	-$30.59M
YoY Change	-165.18%	-57.76%
Interest Expense	$3.277M	-$3.420M
YoY Change	-227.21%	22.84%
% of Operating Profit	46.81%
Other Income/Expense, Net	-$23.50M	$13.60M
YoY Change	-68.9%	-421.75%
Pretax Income	-$16.50M	-$17.00M
YoY Change	-80.88%	-77.83%
Income Tax	$3.100M	$1.233M
% Of Pretax Income
Net Earnings	-$19.60M	-$18.27M
YoY Change	-80.72%	-67.05%
Net Earnings / Revenue	-7.39%	-7.69%
Basic Earnings Per Share	-$0.03	-$0.02
Diluted Earnings Per Share	-$0.03	-$0.02
COMMON SHARES
Basic Shares Outstanding	772.7M shares	772.7M shares
Diluted Shares Outstanding		751.5M shares

Balance Sheet

Concept	2023 Q2	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$108.1M	$110.8M
YoY Change	-48.64%	8.36%
Cash & Equivalents	$108.1M	$110.8M
Short-Term Investments
Other Short-Term Assets	$325.7M	$6.081M
YoY Change	5022.68%	25.85%
Inventory	$73.75M	$75.41M
Prepaid Expenses
Receivables	$211.0M	$121.5M
Other Receivables	$17.11M	$81.92M
Total Short-Term Assets	$433.8M	$406.4M
YoY Change	-12.32%	-46.1%
LONG-TERM ASSETS
Property, Plant & Equipment	$78.88M	$117.7M
YoY Change	-34.82%	-5.6%
Goodwill	$597.4M	$597.4M
YoY Change	3.2%	-15.91%
Intangibles	$782.2M
YoY Change
Long-Term Investments	$27.78M	$41.23M
YoY Change	-74.44%	335.29%
Other Assets	$932.7M	$8.340M
YoY Change	10382.13%	-8.35%
Total Long-Term Assets	$1.725B	$1.763B
YoY Change	-7.99%	13.55%
TOTAL ASSETS
Total Short-Term Assets	$433.8M	$406.4M
Total Long-Term Assets	$1.725B	$1.763B
Total Assets	$2.159B	$2.170B
YoY Change	-8.89%	-5.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$87.90M	$80.50M
YoY Change	56.66%	-14.58%
Accrued Expenses	$98.60M	$106.1M
YoY Change	-23.12%	-32.58%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$27.34M
YoY Change	-100.0%	37.64%
Total Short-Term Liabilities	$226.4M	$222.4M
YoY Change	5.07%	-28.06%
LONG-TERM LIABILITIES
Long-Term Debt	$212.3M	$228.0M
YoY Change	-2.5%	5.39%
Other Long-Term Liabilities	$51.90M	$27.98M
YoY Change	219.64%	78.69%
Total Long-Term Liabilities	$264.2M	$395.4M
YoY Change	-39.31%	3.3%
TOTAL LIABILITIES
Total Short-Term Liabilities	$226.4M	$222.4M
Total Long-Term Liabilities	$264.2M	$395.4M
Total Liabilities	$623.6M	$617.9M
YoY Change	-4.18%	-10.71%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.861B	-$1.841B
YoY Change	12.67%	18.79%
Common Stock	$7.817M	$7.813M
YoY Change	0.14%	13.2%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.535B	$1.552B
YoY Change
Total Liabilities & Shareholders Equity	$2.159B	$2.170B
YoY Change	-8.89%	-5.95%

Cashflow Statement

Concept	2023 Q2	2023 Q1
OPERATING ACTIVITIES
Net Income	-$19.60M	-$18.27M
YoY Change	-80.72%	-67.05%
Depreciation, Depletion And Amortization	$21.50M	$26.45M
YoY Change	-23.2%	-4.92%
Cash From Operating Activities	-$365.0K	-$22.65M
YoY Change	-96.82%	14.06%
INVESTING ACTIVITIES
Capital Expenditures	$6.013M	$3.037M
YoY Change	-211.79%	-157.84%
Acquisitions
YoY Change
Other Investing Activities	$522.0K	-$4.680M
YoY Change	-99.54%	-1444.83%
Cash From Investing Activities	-$5.491M	-$7.717M
YoY Change	-105.06%	57.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.462M	-$13.12M
YoY Change	-71.79%	66.25%
NET CHANGE
Cash From Operating Activities	-365.0K	-$22.65M
Cash From Investing Activities	-5.491M	-$7.717M
Cash From Financing Activities	3.462M	-$13.12M
Net Change In Cash	-2.394M	-$42.36M
YoY Change	-102.19%	30.63%
FREE CASH FLOW
Cash From Operating Activities	-$365.0K	-$22.65M
Capital Expenditures	$6.013M	$3.037M
Free Cash Flow	-$6.378M	-$25.68M
YoY Change	4.59%	75.86%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000944809
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2023Q1	dei	Trading Symbol TradingSymbol	OPK
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-33528
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	OPKO Health, Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	75-2402409
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	4400 Biscayne Blvd.
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Miami
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33137
CY2023Q1	dei	City Area Code CityAreaCode	(305)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	575-4100
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	772650812	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	110830000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	153191000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	121486000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	127312000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	75411000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	74060000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	98691000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	39962000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	406418000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	394525000	usd
CY2023Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	80853000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	82879000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	803616000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	823520000	usd
CY2023Q1	opk	In Process Researchand Development InProcessResearchandDevelopment	195000000	usd
CY2022Q4	opk	In Process Researchand Development InProcessResearchandDevelopment	195000000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	597380000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	595851000	usd
CY2023Q1	us-gaap	Long Term Investments LongTermInvestments	41231000	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	28080000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	36832000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	38725000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	8340000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	8679000	usd
CY2023Q1	us-gaap	Assets Assets	2169670000	usd
CY2022Q4	us-gaap	Assets Assets	2167259000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	80503000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	66993000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	106058000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	98269000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11490000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11628000	usd
CY2023Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	3050000	usd
CY2023Q1	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	24371000	usd
CY2022Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	33540000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	222422000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	213480000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	26462000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	27963000	usd
CY2023Q1	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	211328000	usd
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	210371000	usd
CY2023Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	129668000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	126426000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	27980000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	27371000	usd
CY2023Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	395438000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	392131000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	617860000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	605611000	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	781306164	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	781306164	shares
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	237577000	usd
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	7813000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	7813000	usd
CY2023Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	8655082	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	8655082	shares
CY2023Q1	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	1791000	usd
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	1791000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3424589000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3421872000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-37611000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-43323000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1841190000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1822923000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1551810000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1561648000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2169670000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2167259000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	329219000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	75642000	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	117537000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	32605000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18312000	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	136000	usd
CY2022Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-106000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	21474000	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	22025000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	268171000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	401643000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-30594000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-72424000	usd
CY2023Q1	opk	Interest Income Nonoperating InterestIncomeNonoperating	1030000	usd
CY2022Q1	opk	Interest Income Nonoperating InterestIncomeNonoperating	10000	usd
CY2023Q1	opk	Interest Expense Nonoperating InterestExpenseNonoperating	3391000	usd
CY2022Q1	opk	Interest Expense Nonoperating InterestExpenseNonoperating	2662000	usd
CY2023Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-1059000	usd
CY2022Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-132000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	17017000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1442000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	13597000	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4226000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-16997000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-76650000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1233000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-21266000	usd
CY2023Q1	opk	Income Loss From Continuing Operations Before Investments In Investees Extraordinary Items Net Of Tax IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax	-18230000	usd
CY2022Q1	opk	Income Loss From Continuing Operations Before Investments In Investees Extraordinary Items Net Of Tax IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax	-55384000	usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-37000	usd
CY2022Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-49000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-18267000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-55433000	usd
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	751506257	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	751506257	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	660302426	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	660302426	shares
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-18267000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-55433000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	5712000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-920000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12555000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-56353000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1561648000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2717000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-18267000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	5712000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1551810000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1685126000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7617000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	136000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-55433000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-920000	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1614884000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-18267000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-55433000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	26446000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	27814000	usd
CY2023Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	678000	usd
CY2022Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	678000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	296000	usd
CY2022Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	281000	usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-37000	usd
CY2022Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-49000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2717000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7617000	usd
CY2023Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-1845000	usd
CY2022Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-61000	usd
CY2023Q1	opk	Increase Decrease In Equity Securities Fvni And Derivative Instruments IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments	7130000	usd
CY2022Q1	opk	Increase Decrease In Equity Securities Fvni And Derivative Instruments IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments	-1299000	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	136000	usd
CY2022Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-106000	usd
CY2023Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	102000	usd
CY2022Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-22356000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-7364000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-44421000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1306000	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	9463000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	58902000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2612000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-772000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-511000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	12759000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	16143000	usd
CY2023Q1	opk	Increase Decreasein Foreign Currency Measurement IncreaseDecreaseinForeignCurrencyMeasurement	-2355000	usd
CY2022Q1	opk	Increase Decreasein Foreign Currency Measurement IncreaseDecreaseinForeignCurrencyMeasurement	2197000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	2000	usd
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-4000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	9547000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-36177000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22647000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19856000	usd
CY2023Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	5000000	usd
CY2022Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	320000	usd
CY2022Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	348000	usd
CY2023Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	3037000	usd
CY2022Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	5251000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7717000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4903000	usd
CY2023Q1	opk	Proceeds From Stock Options Exercised Net Of Tax Withholdings ProceedsFromStockOptionsExercisedNetOfTaxWithholdings	0	usd
CY2022Q1	opk	Proceeds From Stock Options Exercised Net Of Tax Withholdings ProceedsFromStockOptionsExercisedNetOfTaxWithholdings	136000	usd
CY2023Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	165288000	usd
CY2022Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	1649166000	usd
CY2023Q1	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	175407000	usd
CY2022Q1	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	1657193000	usd
CY2023Q1	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	3000000	usd
CY2022Q1	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-13119000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-7891000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1122000	usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	221000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-42361000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-32429000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	153191000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	134710000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	110830000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	102281000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	3830000	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	3420000	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	477000	usd
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1063000	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	960000	usd
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	usd
CY2023Q1	opk	Numberof Sales Employees NumberofSalesEmployees	180	employee
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	34200000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	39900000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from these estimates.</span>
CY2023Q1	us-gaap	Inventory Write Down InventoryWriteDown	1400000	usd
CY2022Q1	us-gaap	Inventory Write Down InventoryWriteDown	1300000	usd
CY2022Q4	opk	Business Combination Recognized Identifiable Assets Acquiredand Liabilities Assumed Goodwilland Intangible Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets	1600000000	usd
CY2023Q1	opk	Business Combination Recognized Identifiable Assets Acquiredand Liabilities Assumed Goodwilland Intangible Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets	1600000000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	597400000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	595900000	usd
CY2023Q1	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	1000000000	usd
CY2022Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	1000000000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	21500000	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	22000000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	5000000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	5800000	usd
CY2023Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	6000000	usd
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of credit risk and allowance for credit losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Financial instruments that potentially subject us to concentrations of credit risk consist primarily of accounts receivable. Substantially all of our accounts receivable are with either companies in the healthcare industry or patients. However, credit risk is limited due to the number of our clients as well as their dispersion across many different geographic regions.</span>
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2100000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	4200000	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	85200	usd
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	87600	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2700000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7600000	usd
CY2023Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1000000	usd
CY2022Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1100000	usd
CY2023Q1	opk	Stock Issued During Period Shares Number Of Stock Options Exercised StockIssuedDuringPeriodSharesNumberOfStockOptionsExercised	0	shares
CY2023Q1	opk	Stock Issued During Period Shares Stock Options And Restricted Stock Units Exercised Net Of Shares Surrendered In Lieu Of Cash Payment StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsExercisedNetOfSharesSurrenderedInLieuOfCashPayment	0	shares
CY2022Q1	opk	Stock Issued During Period Shares Number Of Stock Options Exercised StockIssuedDuringPeriodSharesNumberOfStockOptionsExercised	55750	shares
CY2022Q1	opk	Stock Issued During Period Shares Stock Options And Restricted Stock Units Exercised Net Of Shares Surrendered In Lieu Of Cash Payment StockIssuedDuringPeriodSharesStockOptionsAndRestrictedStockUnitsExercisedNetOfSharesSurrenderedInLieuOfCashPayment	55750	shares
CY2022Q1	opk	Stock Issued During Period Shares Number Of Stock Options Exercised StockIssuedDuringPeriodSharesNumberOfStockOptionsExercised	55750	shares
CY2022Q1	opk	Shares Surrendered In Lieu Of Cash Payment SharesSurrenderedInLieuOfCashPayment	0	shares
CY2023Q1	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	123553000	usd
CY2022Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	131474000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2067000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	4162000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	121486000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	127312000	usd
CY2023Q1	us-gaap	Other Inventory Supplies OtherInventorySupplies	30176000	usd
CY2022Q4	us-gaap	Other Inventory Supplies OtherInventorySupplies	31275000	usd
CY2023Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	39260000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	37139000	usd
CY2023Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	2897000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	2449000	usd
CY2023Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	7671000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	6771000	usd
CY2023Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	4593000	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	3574000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	75411000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	74060000	usd
CY2023Q1	opk	Taxes Recoverable Current TaxesRecoverableCurrent	7653000	usd
CY2022Q4	opk	Taxes Recoverable Current TaxesRecoverableCurrent	8191000	usd
CY2023Q1	us-gaap	Supplies Supplies	9058000	usd
CY2022Q4	us-gaap	Supplies Supplies	7918000	usd
CY2023Q1	us-gaap	Prepaid Insurance PrepaidInsurance	1628000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	4496000	usd
CY2023Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	74271000	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	13105000	usd
CY2023Q1	us-gaap	Other Assets Current OtherAssetsCurrent	6081000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	6252000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	98691000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	39962000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	422881000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	398959000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	803616000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	823520000	usd
CY2023Q1	opk	Inventory Received Not Invoiced Current InventoryReceivedNotInvoicedCurrent	7830000	usd
CY2022Q4	opk	Inventory Received Not Invoiced Current InventoryReceivedNotInvoicedCurrent	7830000	usd
CY2023Q1	opk	Accrued Commitmentsand Contingencies Current AccruedCommitmentsandContingenciesCurrent	4006000	usd
CY2022Q4	opk	Accrued Commitmentsand Contingencies Current AccruedCommitmentsandContingenciesCurrent	4295000	usd
CY2023Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	40323000	usd
CY2022Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	33765000	usd
CY2023Q1	opk	Accrued Clinical Trials Current AccruedClinicalTrialsCurrent	5708000	usd
CY2022Q4	opk	Accrued Clinical Trials Current AccruedClinicalTrialsCurrent	4700000	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	65000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	62000	usd
CY2023Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2968000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2809000	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2041000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1820000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	43117000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	42988000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	106058000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	98269000	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	1114000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	974000	usd
CY2023Q1	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	8801000	usd
CY2022Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	9098000	usd
CY2023Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	7890000	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	7089000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	140000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	138000	usd
CY2023Q1	us-gaap	Other Liabilities And Deferred Revenue Noncurrent OtherLiabilitiesAndDeferredRevenueNoncurrent	10035000	usd
CY2022Q4	us-gaap	Other Liabilities And Deferred Revenue Noncurrent OtherLiabilitiesAndDeferredRevenueNoncurrent	10072000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	27980000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	27371000	usd
CY2022Q1	us-gaap	Goodwill Goodwill	633874000	usd
CY2022Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	38023000	usd
CY2023Q1	opk	Goodwill Acquired Disposed Of During Period GoodwillAcquiredDisposedOfDuringPeriod	-173000	usd
CY2023Q1	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	1702000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	597380000	usd
CY2023Q1	opk	Equity Method Investment Excluding Variable Interest Entity EquityMethodInvestmentExcludingVariableInterestEntity	69000	usd
CY2023Q1	us-gaap	Equity Method Investment Underlying Equity In Net Assets EquityMethodInvestmentUnderlyingEquityInNetAssets	3340000	usd
CY2022Q4	opk	Equity Method Investment Excluding Variable Interest Entity EquityMethodInvestmentExcludingVariableInterestEntity	103000	usd
CY2022Q4	us-gaap	Equity Method Investment Underlying Equity In Net Assets EquityMethodInvestmentUnderlyingEquityInNetAssets	4120000	usd
CY2023Q1	opk	Equity Method Investment Variable Interest Entity EquityMethodInvestmentVariableInterestEntity	798000	usd
CY2023Q1	opk	Equity Method Investment Variable Interest Entity Underlying Equity In Net Assets EquityMethodInvestmentVariableInterestEntityUnderlyingEquityInNetAssets	1368000	usd
CY2022Q4	opk	Equity Method Investment Variable Interest Entity EquityMethodInvestmentVariableInterestEntity	800000	usd
CY2022Q4	opk	Equity Method Investment Variable Interest Entity Underlying Equity In Net Assets EquityMethodInvestmentVariableInterestEntityUnderlyingEquityInNetAssets	1370000	usd
CY2023Q1	us-gaap	Equity Method Investments Fair Value Disclosure EquityMethodInvestmentsFairValueDisclosure	34414000	usd
CY2022Q4	us-gaap	Equity Method Investments Fair Value Disclosure EquityMethodInvestmentsFairValueDisclosure	21120000	usd
CY2023Q1	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	543000	usd
CY2022Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	648000	usd
CY2023Q1	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	5381000	usd
CY2022Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	5381000	usd
CY2023Q1	opk	Stock Optionand Warrant Investments StockOptionandWarrantInvestments	26000	usd
CY2022Q4	opk	Stock Optionand Warrant Investments StockOptionandWarrantInvestments	28000	usd
CY2023Q1	us-gaap	Long Term Investments LongTermInvestments	41231000	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	28080000	usd
CY2023Q1	us-gaap	Equity Method Investment Quoted Market Value EquityMethodInvestmentQuotedMarketValue	1500000	usd
CY2022Q4	us-gaap	Equity Method Investment Quoted Market Value EquityMethodInvestmentQuotedMarketValue	1300000	usd
CY2023Q1	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-105000	usd
CY2022Q1	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-1162000	usd
CY2023Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-105000	usd
CY2022Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-1162000	usd
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	244643000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	256251000	usd
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	244643000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	256251000	usd
CY2023Q1	opk	Debt Instruments Numberof Financial Institutions DebtInstrumentsNumberofFinancialInstitutions	13	institution
CY2022Q4	opk	Debt Instruments Numberof Financial Institutions DebtInstrumentsNumberofFinancialInstitutions	13	institution
CY2023Q1	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	104888000	usd
CY2023Q1	us-gaap	Line Of Credit LineOfCredit	22260000	usd
CY2022Q4	us-gaap	Line Of Credit LineOfCredit	31820000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	52074000	usd
CY2023Q1	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	543000	usd
CY2023Q1	us-gaap	Equity Method Investments Fair Value Disclosure EquityMethodInvestmentsFairValueDisclosure	34414000	usd
CY2023Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	87057000	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	1179000	usd
CY2023Q1	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	2063000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	102773000	usd
CY2022Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	648000	usd
CY2022Q4	us-gaap	Equity Method Investments Fair Value Disclosure EquityMethodInvestmentsFairValueDisclosure	21120000	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	124569000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	1036000	usd
CY2022Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	2159000	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	1200000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	1000000	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	1200000	usd
CY2023Q1	us-gaap	Purchase Obligation PurchaseObligation	52800000	usd
CY2023Q1	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	4800000	usd
CY2022Q1	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	3200000	usd
CY2023Q1	opk	Accrued Expense Payor Overpayment Reimbursement Liability AccruedExpensePayorOverpaymentReimbursementLiability	2200000	usd
CY2022Q4	opk	Accrued Expense Payor Overpayment Reimbursement Liability AccruedExpensePayorOverpaymentReimbursementLiability	1800000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	138000	usd
CY2023Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	140000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-2000	usd
CY2023Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-30594000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-72424000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	26446000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	27814000	usd
CY2023Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	-37000	usd
CY2022Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	-49000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	237577000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	329219000	usd
CY2023Q1	us-gaap	Assets Assets	2169670000	usd
CY2022Q4	us-gaap	Assets Assets	2167259000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	597380000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	595851000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	36832000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	38725000	usd
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	10858000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	9898000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11490000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11628000	usd
CY2023Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2968000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2809000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	26462000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	27963000	usd
CY2023Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	7890000	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	7089000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y1M6D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y
CY2023Q1	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P6Y7M6D
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P6Y6M
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.045
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.044
CY2023Q1	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.043
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.038
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	9286000	usd
CY2023Q1	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	2482000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	8464000	usd
CY2023Q1	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	2724000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	5295000	usd
CY2023Q1	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	2062000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	4030000	usd
CY2023Q1	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	1402000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	3858000	usd
CY2023Q1	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	587000	usd
CY2023Q1	opk	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	11910000	usd
CY2023Q1	opk	Finance Lease Liability Payments Due After Year Four FinanceLeaseLiabilityPaymentsDueAfterYearFour	1990000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	42843000	usd
CY2023Q1	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	11247000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4891000	usd
CY2023Q1	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	389000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	37952000	usd
CY2023Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	10858000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	4100000	usd
CY2023Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	700000	usd
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	600000	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	4600000	usd
CY2022Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	700000	usd
CY2022Q1	us-gaap	Variable Lease Cost VariableLeaseCost	400000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	3872000	usd
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	4288000	usd
CY2023Q1	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	108000	usd
CY2022Q1	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	33000	usd
CY2023Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	656000	usd
CY2022Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	498000	usd
CY2023Q1	opk	Payments For Leases PaymentsForLeases	4636000	usd
CY2022Q1	opk	Payments For Leases PaymentsForLeases	4819000	usd

Files In Submission

Name	View Source	Status
0000944809-23-000021-index-headers.html	Edgar Link	pending
0000944809-23-000021-index.html	Edgar Link	pending
0000944809-23-000021.txt	Edgar Link	pending
0000944809-23-000021-xbrl.zip	Edgar Link	pending
ex10-1modexxmercklrca.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
opk-20230331.htm	Edgar Link	pending
opk-20230331.xsd	Edgar Link	pending
opk-3312023xex311.htm	Edgar Link	pending
opk-3312023xex312.htm	Edgar Link	pending
opk-3312023xex321.htm	Edgar Link	pending
opk-3312023xex322.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
opk-20230331_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
opk-20230331_def.xml	Edgar Link	unprocessable
opk-20230331_lab.xml	Edgar Link	unprocessable
opk-20230331_pre.xml	Edgar Link	unprocessable
opk-20230331_htm.xml	Edgar Link	completed
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OPK
OPKO HEALTH, INC. Stock $opk

2023 Q2 Form 10-Q Financial Statement

#000094480923000021 Filed on May 03, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OPK OPKO HEALTH, INC. Stock $opk

2023 Q2 Form 10-Q Financial Statement

#000094480923000021 Filed on May 03, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OPK
OPKO HEALTH, INC. Stock $opk